Innovative Solutions for Liver Disease at AASLD 2025
SINGAPORE — HistoIndex, a leader in digital pathology solutions for chronic liver disease, is set to showcase remarkable advancements at The Liver Meeting 2025 (TLM 2025), organized by the American Association for the Study of Liver Diseases (AASLD). The meeting provides a significant platform for scientists, clinicians, and industry experts in hepatology from various regions to discuss their findings and innovations. The event is expected to have a substantial impact in the realm of liver disease diagnostics.
Introducing FibroSIGHT™ Plus
This year signifies a pivotal moment for HistoIndex as it broadens its operations beyond just clinical trials and research to include clinical diagnostics specifically targeting Metabolic Dysfunction–Associated Steatohepatitis (MASH). A key highlight will be the introduction of FibroSIGHT™ Plus, a Laboratory Developed Test (LDT) that is to be available for clinical use from a CLIA-accredited laboratory in the United States. This innovative diagnostic solution aims to enhance the accuracy of liver fibrosis assessments, consequently leading to improved patient management practices within the rapidly advancing field of MASH therapeutics. Dr. Yukti Choudhury, Chief Development Officer at HistoIndex, expressed enthusiasm about providing diagnostic standards comparable to those used in clinical trials.
Significant Clinical Advancement in Diagnostics
The state-of-the-art FibroSIGHT™ Plus will utilize a novel approach to deliver detailed quantitative evaluations of liver fibrosis, enabling healthcare professionals to make more informed treatment decisions. This upgrade aims to refine patient diagnostics within clinical settings, creating a direct benefit for patients suffering from MASH.
Scientific Contributions to TLM 2025
HistoIndex also emphasizes its commitment to scientific advancement, participating in TLM 2025 with an impressive line-up of presentations. The company will be providing one oral presentation along with ten poster presentations, which includes two posters of distinction and one late-breaking poster. These presentations highlight HistoIndex's technology in delivering significant contributions to understanding diverse liver diseases and their therapeutic contexts.
Highlighting Key Scientific Presentations
Among the notable presentations will be findings from two posters of distinction that showcase enhanced fibrosis detection techniques for advanced MASH stages and cirrhosis. The company aims to underline the potentials within these critical areas where there is a dire need for effective treatments. Additionally, an oral presentation will delve into pioneering applications of Artificial Intelligence (AI) in biopsy analysis, demonstrating its impact beyond MASH into other liver-related conditions.
Breakfast Meeting and Networking Opportunities
Alongside its scientific sessions, HistoIndex will host a breakfast meeting to explore collaborative opportunities, particularly its joint initiatives with the National Institutes of Health (NIH) and Virginia Commonwealth University (VCU). This meeting will highlight the application of advanced imaging technologies and AI analytics within key research cohorts. Clinicians interested in participating are encouraged to connect early due to limited seating.
Evening Reception Celebration
In addition to its breakfast meeting, HistoIndex will be organizing an evening reception that celebrates its expansion into clinical diagnostics through the launch of FibroSIGHT™ Plus, focusing on its role in everyday patient care for MASH. The event will feature special guest Dr. Naim Alkhouri, who will share new findings regarding the effectiveness of AI in the evaluation of liver fibrosis.
Visit HistoIndex at TLM 2025
Attendees of TLM 2025 are invited to visit HistoIndex at Booth #645. Here, the company will feature an expanded exhibition, showcasing the FibroSIGHT™ Plus technology and how it is shaping the future of liver disease diagnostics through AI-driven approaches. The team at HistoIndex is eager to engage with attendees to answer questions and explore collaborative research opportunities related to liver health.
About HistoIndex
Founded in 2010, HistoIndex stands as a pioneer in developing automated imaging solutions to visualize and quantify fibrosis in biological tissues. Merging advanced biophotonic technology with AI-based analytics, the company aims to enhance drug efficacy assessment and foster improvements in how fibrosis is understood and treated. HistoIndex’s groundbreaking digital pathology solutions focus on expediting pharmaceutical developments and transforming clinical practices for liver disease management.
Frequently Asked Questions
What is FibroSIGHT™ Plus?
FibroSIGHT™ Plus is a Laboratory Developed Test (LDT) designed to provide enhanced diagnostics for liver fibrosis assessment, focusing on Metabolic Dysfunction–Associated Steatohepatitis (MASH).
When will the TLM 2025 event take place?
The Liver Meeting 2025 will occur from November 7 to November 11, 2025.
What is the significance of HistoIndex's presence at TLM 2025?
HistoIndex will present critical research findings demonstrating the effectiveness of its digital pathology technology, thereby highlighting advancements in diagnostics for chronic liver diseases.
Who can attend the HistoIndex Breakfast Meeting?
Hepatologists and gastroenterologists are invited to the HistoIndex Breakfast Meeting, but early registration is advised due to limited seating.
What breakthroughs will be showcased in the evening reception?
The evening reception will discuss new data regarding AI-driven fibrosis assessment techniques and their implications for MASH treatment efficacy.
